Medpace (MEDP) Stock Price, News & Analysis $283.19 +1.74 (+0.62%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$279.16▼$289.1450-Day Range$227.52▼$283.1952-Week Range$167.00▼$289.14Volume168,768 shsAverage Volume177,272 shsMarket Capitalization$8.69 billionP/E Ratio33.16Dividend YieldN/APrice Target$277.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Medpace MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2.1% Downside$277.33 Price TargetShort InterestBearish5.31% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment1.19Based on 5 Articles This WeekInsider TradingSelling Shares$137.72 M Sold Last QuarterProj. Earnings Growth16.18%From $8.65 to $10.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector176th out of 940 stocksCommercial Physical Research Industry5th out of 13 stocks 1.5 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $277.33, Medpace has a forecasted downside of 2.1% from its current price of $283.19.Amount of Analyst CoverageMedpace has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.31% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Medpace has recently increased by 7.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 3.4 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medpace this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows5 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,721,097.00 in company stock.Percentage Held by Insiders25.70% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 16.18% in the coming year, from $8.65 to $10.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 33.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.54.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 33.16, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.71.Price to Book Value per Share RatioMedpace has a P/B Ratio of 22.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesDecember 10, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Hits New 12-Month High at $289.14December 3, 2023 | americanbankingnews.comAugust J. Troendle Sells 7,871 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) StockDecember 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 3, 2023 | americanbankingnews.comMedpace Investors, Llc Sells 24,039 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) StockDecember 3, 2023 | americanbankingnews.comMedpace Investors, Llc Sells 21,257 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) StockDecember 2, 2023 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle Sells 21,833 SharesDecember 1, 2023 | americanbankingnews.comInsider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) Major Shareholder Sells 25,000 Shares of StockNovember 30, 2023 | msn.comMedpace Holdings 10% owner sells over 46K sharesDecember 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 30, 2023 | finance.yahoo.comAt US$272, Is Medpace Holdings, Inc. (NASDAQ:MEDP) Worth Looking At Closely?November 28, 2023 | benzinga.comMedpace Hldgs Insider Trades Send a SignalNovember 27, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Medpace, Doximity and BiodesixNovember 23, 2023 | benzinga.comMedpace Hldgs CEO Trades Company's StockNovember 23, 2023 | msn.comMedpace Holdings 10% owner discloses sale of 25K sharesNovember 17, 2023 | benzinga.comCEO of Medpace Hldgs Sold $21.22M In StockNovember 11, 2023 | msn.com2023 Warm 98.5 Ice Rink season at Summit Park starts this SaturdayNovember 8, 2023 | msn.comThis Health Care Play Breaks Out After Doubling The Market's GainsNovember 8, 2023 | finance.yahoo.comIf EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An OpportunityNovember 5, 2023 | morningstar.comMedpace Holdings Inc MEDPNovember 3, 2023 | msn.comMedpace Holdings (MEDP) Price Target Increased by 8.05% to 294.27November 3, 2023 | msn.comMedpace: Delivering Strong Results And Shareholder ReturnsNovember 3, 2023 | msn.comMedpace: Delivering Strong Results And Shareholder ReturnsNovember 1, 2023 | msn.comIs Medpace (MEDP) Outperforming Other Medical Stocks This Year?October 25, 2023 | msn.comMedpace upgraded at Baird after another earnings beatOctober 25, 2023 | finance.yahoo.comAn Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 30% UndervaluedOctober 25, 2023 | finance.yahoo.comMedpace Holdings, Inc. (NASDAQ:MEDP) Q3 2023 Earnings Call TranscriptOctober 25, 2023 | finance.yahoo.comMedpace Holdings, Inc.: Medpace Earnings: Robust Demand Exceeds Expectations; Raising Fair Value Estimate to $239See More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/23/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,200Year FoundedN/APrice Target and Rating Average Stock Price Target$277.33 High Stock Price Target$289.00 Low Stock Price Target$270.00 Potential Upside/Downside-2.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$8.54 Trailing P/E Ratio33.16 Forward P/E Ratio32.74 P/E GrowthN/ANet Income$245.37 million Net Margins15.33% Pretax Margin17.89% Return on Equity68.48% Return on Assets19.37% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$1.46 billion Price / Sales5.95 Cash Flow$8.64 per share Price / Cash Flow32.77 Book Value$12.42 per share Price / Book22.80Miscellaneous Outstanding Shares30,680,000Free Float22,797,000Market Cap$8.69 billion OptionableOptionable Beta1.35 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 67)Chairman & CEO Comp: $1.68MMr. Jesse J. Geiger BBA (Age 49)CPA, President Comp: $876.92kMr. Kevin M. Brady (Age 48)CFO & Treasurer Comp: $636.58kMs. Susan E. Burwig BSN (Age 60)MA, Executive Vice President of Operations Comp: $1MMr. Stephen P. Ewald J.D. (Age 54)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $826.17kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 62)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHIncyteNASDAQ:INCYPenumbraNYSE:PENVerona PharmaNASDAQ:VRNAView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 5,723 shares on 12/6/2023Ownership: 0.025%Medpace Investors, LlcSold 24,039 sharesTotal: $6.57 M ($273.26/share)Wellington Management Group LLPBought 319,210 shares on 12/1/2023Ownership: 1.373%August J TroendleSold 7,871 sharesTotal: $2.14 M ($272.18/share)American Century Companies Inc.Bought 13,806 shares on 11/30/2023Ownership: 0.172%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medpace stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price target for 2024? 2 Wall Street research analysts have issued 12-month price targets for Medpace's stock. Their MEDP share price targets range from $270.00 to $289.00. On average, they expect the company's share price to reach $277.33 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2023? Medpace's stock was trading at $212.41 on January 1st, 2023. Since then, MEDP shares have increased by 33.3% and is now trading at $283.19. View the best growth stocks for 2023 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings data on Monday, October, 23rd. The company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.05 by $0.17. The business earned $492.50 million during the quarter, compared to the consensus estimate of $475.79 million. Medpace had a trailing twelve-month return on equity of 68.48% and a net margin of 15.33%. The business's quarterly revenue was up 28.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.05 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap Quality ETF (XMHQ), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY23 earnings guidance on Monday, October, 23rd. The company provided EPS guidance of $8.54-8.66 for the period, compared to the consensus earnings per share estimate of $8.39. The company issued revenue guidance of $1.87-1.89 billion, compared to the consensus revenue estimate of $1.87 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by a number of retail and institutional investors. Top institutional investors include Fuller & Thaler Asset Management Inc. (2.08%), Invesco Ltd. (1.99%), Riverbridge Partners LLC (1.99%), Boston Trust Walden Corp (1.77%), Wellington Management Group LLP (1.37%) and Morgan Stanley (1.01%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MEDP) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.